Every source, listed.

Primary literature and regulatory sources

The numbered references below cover every claim cited on this site. PubMed and PMC links are preferred where available; ClinicalTrials.gov links are used for trial-registry entries; the FDA briefing-materials PDFs and the WADA Prohibited List are linked directly to their official locations.

The full citation list is rendered in the references_index field of this content document; the assembler will format it as a numbered list with each entry showing the citation, the DOI (where available), and a hyperlink to the primary source.

Editorial sourcing standards

Every quantitative claim on this site — half-life numbers, dose values, percentage elevations, trial sample sizes, study durations, adverse event frequencies, and regulatory determinations — traces to a numbered reference below. Where the published literature is ambiguous or incomplete, the site says so rather than filling the gap with secondary or non-peer-reviewed sources.

The site does not cite anonymous forum threads, vendor product pages, research-chemical-channel marketing material, or undated YouTube content. The Van Hout 2016 netnographic analysis ^[10] is cited because it is a peer-reviewed academic study of online forum behavior, not because the forum content itself is treated as evidence.

Where a primary source is paywalled and a freely accessible companion (PMC version, preprint, or open-access regulatory document) exists, the open version is linked.

Claims about FDA status reference the official FDA Pharmacy Compounding Advisory Committee briefing materials ^[14][15], not secondary summaries. Claims about WADA status reference the official 2025 Prohibited List ^[16] directly.